Tumor burden as an independent prognostic factor in metastatic renal cell carcinoma (mRCC).

被引：0
|
作者：
Escudier, Bernard J.
Iacovelli, Roberto
Lanoy, Emilie
Albiges, Laurence
Fizazi, Karim
机构：
[1] Inst Gustave Roussy, Villejuif, France
[2] Univ Roma La Sapienza, Deparment Radiol Oncol & Human Pathol, Oncol Unit, I-00185 Rome, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 05期
关键词：
D O I：
10.1200/jco.2012.30.5_suppl.397
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
397
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Tumor response is an independent prognostic factor in patients (pts) treated for metastatic renal cell carcinoma (mRCC)
    Gruenwald, V.
    Lin, X.
    Kalanovic, D.
    McKay, R.
    Perkins, J.
    Simantov, R.
    Choueiri, T.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S642 - S642
  • [2] Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma
    Iacovelli, Roberto
    Lanoy, Emilie
    Albiges, Laurence
    Escudier, Bernard
    BJU INTERNATIONAL, 2012, 110 (11) : 1747 - 1753
  • [3] Early tumor shrinkage (eTS) as a predictive and prognostic factor in metastatic renal cell carcinoma (mRCC).
    Gruenwald, Viktor
    Lin, Xun
    Kalanovic, Daniel
    Simantov, Ronit
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] Serum level of vascular endothelial growth factor (VEGF) as an independent prognostic factor in metastatic renal cell carcinoma (MRCC)
    Negrier, S.
    Chabaud, S.
    Escudier, B.
    Ravaud, A.
    Chevreau, C.
    Blay, J. Y.
    Delva, R.
    Biota, C.
    Perol, D.
    Menetrier-Caux, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] Association of circulating tumor DNA (ctDNA) detection in metastatic renal cell carcinoma (mRCC) with tumor burden
    Maia, Manuel Caitano
    Bergerot, Paulo Gustavo
    Dizman, Nazli
    Hsu, Joann
    Jones, Jeremy
    Choueiri, Toni K.
    Sonpavde, Guru
    Lannnan, Richard B.
    Banks, Kimberly
    Pal, Sumanta K.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] Relationship of tumor mutational burden (TMB) to immunotherapy response in metastatic renal cell carcinoma (mRCC).
    Maia, Manuel C.
    Almeida, Lorena
    Bergerot, Paulo Gustavo
    Dizman, Nazli
    Pal, Sumanta K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [7] Pre-existing hypertension is an independent prognostic factor in metastatic renal cell carcinoma (mRCC) patients treated with sunitinib (SU)
    Derosa, Lisa
    Izzedine, Hassane
    Le Teuff, Gwenael
    Albiges, Laurence
    Escudier, Bernard
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Targeted therapies (TTs) in metastatic renal cell carcinoma (MRCC): Role of metastatic site as a prognostic and predictive factor
    Procopio, G.
    Grassi, P.
    Porcu, L.
    Verzoni, E.
    Testa, I.
    Garanzini, E.
    Biondani, P.
    Pusceddu, S.
    De Braud, F.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S666 - S666
  • [9] Changes in tumor burden and IMDC class after active surveillance (AS) for metastatic renal cell carcinoma (mRCC).
    Bimbatti, Davide
    Sava, Teodoro
    Massari, Francesco
    Ciccarese, Chiara
    Fantinel, Emanuela
    Dalla Volta, Alberto
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [10] Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review
    Gupta, Kiran
    Miller, Jeffrey D.
    Li, Jim Z.
    Russel, Mason W.
    Charbonneau, Claudie
    CANCER TREATMENT REVIEWS, 2008, 34 (03) : 193 - 205
12345